Gene ther­a­py wins the in­side track at EMA; PPD files for IPO

→ Gene ther­a­py mak­er Or­chard Ther­a­peu­tics has been grant­ed an ac­cel­er­at­ed as­sess­ment for OTL-200 by the EMA’s Com­mit­tee for Med­i­c­i­nal Prod­ucts for Hu­man Use (CHMP). The gene ther­a­py — in de­vel­op­ment in part­ner­ship with the San Raf­faele-Telethon In­sti­tute for Gene Ther­a­py (SR-Tiget) in Mi­lan, Italy — be­ing used to­wards the treat­ment of metachro­mat­ic leukody­s­tro­phy.

Phar­ma­ceu­ti­cal Prod­uct De­vel­op­ment has an­nounced that its par­ent com­pa­ny, PPD, Inc has sub­mit­ted a draft to the SEC re­lat­ing to the pro­pos­al of an IPO of the par­ent com­pa­ny’s com­mon stock. Num­ber of shares and price range have not yet been de­ter­mined.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.